Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway

Jingjing Qu¹,²#, Tianli Cheng³#, Li Liu², Jianfu Heng¹,², Xiaobao Liu¹, Ziyi Sun², Wenxiang Wang⁴#, Kunyan Li¹,²#, Nong Yang²#

¹. Department of Clinical Pharmaceutical Research Institution, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, China
². Department of Lung Cancer and Gastroenterology, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, China
³. Thoracic Medicine Department 1, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, China
⁴. The Second Department of Thoracic Surgery, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, China

# Jingjing Qu and Tianli Cheng contributed equally to this work.

Corresponding authors: Pro. Wenxiang Wang, Department of the Second Department of Thoracic Surgery, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, P.R. China. Email: 2460585948@qq.com. Prof. Kunyan Li, Department of Clinical Pharmaceutical Research Institution, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, P.R. China. Email: Lkunyan@163.com. Prof. Nong Yang, Department of Lung Cancer and Gastroenterology, Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 410008, P.R. China. Email: yangnongf0217@163.com.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.09.15; Accepted: 2019.05.12; Published: 2019.06.09

Abstract

Background: In the various cancer, mast cells (MCs) infiltration is correlated with a worse prognosis. There is an increasing evidence that MCs and their mediators are participated in remodeling of the tumor microenvironment and facilitate tumor growth, epithelial-to-mesenchymal transition (EMT) and metastasis.

Methods: The transwell was conducted to evaluate the correlations between MCs and non-small cell lung cancer (NSCLC) cells in vitro. The RNA interference of β-catenin was performed to further explore the signaling pathway. Lung adenocarcinoma cell line A549 and human MC (HMC-1) were subcutaneously injected into BALB/c nude mice. The conventional experiment methods (such as quantitative RT-PCR Western Blot, Immunofluorescence, and ELISA) were used in the present study.

Results: We found that high density of MCs in NSCLC correlates with worse prognosis. The NSCLC cells could release CCL5 and recruit MCs to the tumor microenvironment. Then, we explored that HMC-1 transplantation accelerated the growth of A549 cell in nude mice. Moreover, the MCs-derived factors were responsible for tumor growth. When NSCLC cells were activated, MCs produced various factors that induced EMT and migration. We also identified that CXCL8/interleukin (IL)-8 served as the major modulator containing in the activated MC conditioned medium. Furthermore, MCs and exogenous IL-8 promoted β-catenin phosphorylation in NSCLC cells. Inhibiting the Wnt/β-catenin pathway by RNA interference could revert EMT and migration of NSCLC.

Conclusions: Our study suggests that MCs are recruited into NSCLC microenvironment and improve the EMT and migration of cancer cells, thereby accelerating the growth of NSCLC.

Key words: mast cells; non-small cell lung cancer; epithelial-to-mesenchymal transition; IL-8/Wnt/β-catenin pathway; cell migration

Introduction

Lung cancer is the most common malignant disease of solid tumors in human. In recent decades, the incidence rate of lung cancer has been steadily increasing by 13% each year. Among these,
approximate 85% are non-small cell lung cancer (NSCLC) and about 33% of diagnosed patients with NSCLC have already reached the metastatic phase because of epithelial-to-mesenchymal transition (EMT) and migration [1-2].

Immune cells, which are an important component of tumor stroma, mediate cancer progression by either inhibiting or facilitating tumor EMT and metastasis [3]. NSCLC micro-environment is affluent in a variety of immune cells, including lymphocytes, macrophages, and mast cells (MCs) [4]. It is well known that MCs play a key role in the tumor EMT and migration [5]. MCs are existed in bone marrow, heterogeneous immune cells that are involved in innate and adaptive immune by releasing preformed or newly synthesized soluble modulators [6]. However, the role of MCs in cancer is still unclear, only few data indicate that MCs own the function in tumor improvement [7]. It is reported that MC density correlates with poor prognosis in many types of cancers result from inducing EMT and invasiveness by MCs [8]. It is interesting to us that MCs can benefit of suppressing immune response to resist tumors [9]. Some studies have proved that human NSCLC exhibits a MC infiltrate along with worse overall survival and disease-free survival [10-11]. However, the underlying mechanism of MCs promote NSCLC migration and EMT is still unknown.

We previously have demonstrated that cancer cells recruit MCs in a tumor microenvironment by secreting many cytokines and chemoattractants such as IL-6, TNF-α, GM-CSF, CXCL8/IL-8, and CXCL1/IP10, which can exacerbate the malignant phenotype of cancer cells [12]. Here we assessed the cellular crosstalk between MCs regulator and NSCLC cells in the modulation of EMT and migration. We found that human NSCLC feature has a significant MCs infiltrate whose intensity is positive correlation with the worse prognosis. According to chemo-attraction assays, we demonstrated that NSCLC cells recruit MCs to the tumor micro-environment through releasing of C-C motif chemokine ligand 5(CCL5) which the receptor CCR3 exists on the MCs surface [13]. The human MCs (HMC-1) were kindly obtained from the (Xiayga Hospital of Central South University) and they were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640; Sigma, USA) medium supplemented with 10% fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA), 100 IU/ml penicillin and 100 IU/ml streptomycin at 37°C in a humid atmosphere with 5% CO2. The human MCs (HMC-1) were culture in Iscove’s Modified Dulbecco’s Medium (IMDM) medium containing 10% fetal bovine serum (FBS; Invitrogen) according to our previous description [14]. Human bronchial epithelial cells (HBECs) CM was used as a negative control.

Preparation of conditioned medium

For generating CM of NSCLC cells, NSCLC cells were cultured up in growth medium providing with 5% FBS. These supernatants were carefully collected, filtered and preserved as the cultured medium to stimulate MCs and NSCLC cells. NSCLC cells CM is termed as the control medium throughout the experiments. For producing CM of MCs, MCs were starved overnight and after that the medium was changed with the NSCLC cells CM and these cells were incubated overnight. Subsequently these supernatants were collected, filtered and preserved at -80°C. These MCs were termed as ‘tumor educated’ MCs and the collected medium was named MC CM.

Mast cell recruitment and NSCLC cells assay in vitro

A 24-well transwell chamber (Corning, NY, USA) was used to assess the ability of MC recruitment in vitro. Briefly, 2.5 × 10⁴ NSCLC cells CM were seeded in the lower chamber, then 1 × 10⁵ MCs were seeded into the upper compartment. The upper and lower compartments were divided by an 8 μm polycarbonate membrane coated with 10 μg/ml fibronectin (Santa Cruz, CA, USA). The chambers were placed at CO₂ incubator with 37 °C for 4 h. Subsequently, the samples were filtered, scraped, and fixed in 4% paraformaldehyde for 20 min. After that,
they were washed with PBS and stained with 0.1% crystal violet. Cell migration was assayed by calculating the number of cells. Each experiment was measured in triplicate in the present study.

To evaluate the migrating ability of NSCLC cells, NSCLC cells (1x10⁴) were incubated in the top compartment with serum-free medium in each Transwell insert (Corning Costar, Corning). The MC CM was added to the bottom chambers and cells were incubated with 37 °C for 24 h. The antibodies of α-IL-6, α-IL-8 and α-TNFα were obtained from R&D Systems (Bio-Technne, USA). The next step was the same as MCs recruitment assay.

**RNA extraction, cDNA synthesis, and quantitative RT-PCR**

NSCLC cells which stimulated with MC CM for 48 h were homogenized in 1 mL of the TRIzol reagent (Invitrogen, USA) to isolate total RNA following the manufacturer’s instructions. RNA was then reversely transcribed into cDNA using the All-in-OneTM First Strand cDNA Synthesis kit (AORT-0050; GeneCopoeia, Shanghai, China). Quantitative real-time PCR (qRT-PCR) was conducted on StepOnePlusTM Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) using the PowerUp SYBR® Green Master Mix (Applied Biosystems). The target primers used for qRT-PCR were described in our previous work [14]. β-actin served as a normalization.

**ELISA assay and histamine release**

MCs were starved overnight and treated with NSCLC cells CM overnight. The cytokines and chemoattractants in the MC CM were measured by ELISA (R&D Systems) according to manufacturer’s instructions. Histamine release was conducted using a histamine ELISA kit (IBL, Hamburg, Germany).

**Western blot analysis**

Protein extractions and immunoblotting analysis were exhibited as described in previous study [15]. In brief, NSCLC cells were performed by either MC CM or control medium with/without the stimulation of recombinant IL-8. After that, the protein lysates were gathered after 1 h, 12 h, and 24 h. The following antibodies were used: primary antibody of vimentin (D21h3, 1:1,000; Cell Signaling Technology (CST), Danvers, USA), E-cadherin (ab76055, 1:1,000; Abcam, Cambridge, USA), GAPDH (14C10, 1:1,000; CST), β-catenin (D10A8, 1:1,000; CST), and secondary antibody of goat anti-rabbit (1:5,000) and goat anti-mouse (1:5,000) (Invitrogen). Protein bands were calculated and quantified with the Image J software. The β-actin was normalized as the control.

**Immunohistochemical analysis**

The NSCLC tissue test was constructed using 56 cases from the department of Thoracic Medicine Department, Hunan Cancer Hospital. Informed consent was received from all investigated patients in the present study. All diagnosis of tumors and controls was carefully assessed by an experienced pathologist. The information of the primary antibodies was as following: anti-human tryptase (clone AA1, 1:200; Abcam), vimentin (D21h3, 1:200; CST), and E-cadherin (ab76055, 1:200; Abcam). Specifically, each sample was scored according to our previous experiments [14].

**Immunofluorescence**

The tumor tissue with protein-blocking serum free solution (Dako, Denmark) was collected and they were incubated with the primary antibodies overnight at 4°C. After the sections were washed with TBST (TBS with Tween 20) and incubated with fluorescent dye-conjugated secondary antibodies for 1 h at room temperature, nuclear staining was conducted with 6-diamidino-2-phenylindole, dihydrochloride (DAPI, Invitrogen). The following antibody was incubated with c-Kit (clone AK2, eBioscience). The specific protocol was according to our former study [15].

**In vivo mast cell recruitment assay**

All mouse experiments were performed following the rules of the Animal Center of Hunan Cancer Hospital. 1 × 10⁷ NSCLC cells were suspended in matrigel (1:8; BD Biosciences, San Jose, USA) and were subcutaneously injected into the right dorsal area of male BALB/c nude mice. When the volume of the xenografts attained about 40 mm³, the mice were intravenously injected with HMC-1 (approximately 1 × 10⁶ with each mouse). Mice were then sacrificed at 1, 2, and 7 d after the injection. To further validate the role of role of CCL5 in the recruitment of MCs in NSCLC in vivo, the CCL5-siRNA were synthesized by Shanghai GenePhama Co., Ltd. (Shanghai, China) and transfected to A549 cell. The CCL5-siRNA sequence was S: 5’- GCCCACAUCAAGGAGUAUUTT-3’, A:5’- AAUACCUUUGAUGUGGCTT-3’.

**Experiments in mice**

The 4 weeks’ old male BALB/c nude mice were applied according to our previous research [14]. For animal experiments, we subcutaneously injected into the right dorsal portion of these nude mice with lung adenocarcinoma cell line A549 (1x10⁷ per mouse), HMC-1 (1x10⁶ per mouse) or mixed together (A549 and HMC-1). The length (termed as “a”) and the width (termed as “b”) of the xenografts of tumors were examined in mice. The xenograft volumes
(termed as “V”) were analyzed according to the formula, \( V (\text{mm}^3) = a \times b^2/2 \). The mice were killed post 3 weeks’ injection and tumor xenografts were collected, removed, weighed, and photographed. Then, the sections were further performed using hematoxylin and eosin (H&E) staining, western blot, immunohistochemistry, and qRT-PCR.

**Statistical analysis**

Statistical significance was assessed by Student’s unpaired \( t \)-test in different experiment groups. Furthermore, for the comparison analysis over two groups, the ANOVA software was used. GraphPad Prism 6 software (San Diego, USA) was conducted and a “\( p \)” value < 0.05 was considered statistically significant.

**Results**

1 **Mast cell increased in human NSCLC and correlated with worse prognosis**

We analyzed MCs infiltrate in 56-paired primary NSCLC and distant normal tissues (at least 5 cm distal to the tumor lesion). Compared with normal samples, NSCLC samples expressed much more infiltration in MCs. A typical example of cell staining by tryptase antibody was presented in Figure 1A and 1B.

For exploring the correction between clinic-pathological features, prognosis and MCs infiltrate, NSCLC samples were divided into two groups: one with high expression of tryptase (+++, +++) which represented 68% (38 of 56) of collected patients; the other one with lower expression of tryptase (+, -), which represented 32% (18 of 56). The group of NSCLC samples with intense tryptase staining seemed to be the advance stage (\( P < 0.05 \)). However, the tryptase staining is not correlated with age, gender and pathological pattern and lymph node metastasis (Table 1). These results suggested that MCs infiltrate in NSCLC tissues were much higher compared with the normal lung tissues. MCs presence and more intensity positively correlated with worse prognosis (Figure 1C, HR = 3.49, 95% CI was 1.44-8.45, \( P=0.005 \)).

2 **Recruitment of mast cells by NSCLC cells: a role for CCL5**

To evaluate how did the MCs recruitment to the tumor micro-environment by NSCLC cells, we performed chemotaxis assays in vitro. We examined the capacity of CM from the NSCLC cell lines (\( 1 \times 10^5 \) A549 and \( 1 \times 10^5 \) SPC-α-1) in the lower chambers. Then the \( 1 \times 10^5 \) MCs were seeded in the upper chambers to induce the migration potency of MCs according to a fibronectin matrix. The data indicated that CM from each cell line (A549 and SPC-α-1) could induce the migration of HMC-1 (Figure 2A). The results indicated that some cytokines secreted by

---

*Figure 1:* Mast cell is increased in human NSCLC and correlates with worse prognosis. (A) Immuno-histochemical analysis of tryptase in human NSCLC tissue compared to the normal non-tumor tissues. (B) The degree of tryptase-positive cell staining was evaluated. In the NSCLC tissue showed more MCs infiltration than the normal tissue. (C) Kaplan-curve analysis of overall survival of MC in NSCLC.
NSCLC cells were responsible for the chemoattractant effect on HMC-1. Further analysis suggested that a candidate for the chemoattractant role is CCL5, and others have validated that NSCLC cells produce CCL5, and HMC-1 express CCL5 receptor CCR1 [16-17]. As shown in Figure 2B, NSCLC cells produce high level of CCL5, but not HBECs. Once we neutralized the CCL5 in the A549 CM, the MCs chemotaxix effect was inhibited (Figure 2C). These data demonstrated that NSCLC cells secreted CCR5 to induce MCs recruitment.

| Table 1. Correlations of tryptase infiltration with clinic-pathological features of NSCLC patients |
|-------------------------------------------------|--------------|-----------------|
| Features                                     | No of patients | Tryptase infiltration | P value  |
|                                                | Low | High |                |
| Age (yrs.)                                    |     |      |                |
| ≤ 60                                           | 29  | 11   | 18             |
| > 60                                           | 27  | 7    | 20             |
| Gender                                         |     |      |                |
| Male                                           | 35  | 9    | 26             |
| Female                                         | 21  | 9    | 12             |
| Clinical stage                                 |     |      |                |
| I-II                                          | 23  | 15   | 8              |
| III-IV                                        | 33  | 3    | 30             |
| Pathologic types                               |     |      |                |
| Squamous carcinomas                            | 16  | 5    | 11             |
| Adenocarcinoma                                 | 40  | 13   | 27             |

NSCLC cells induce mast cell activation

Once the MCs activation, it can release histamine, cytokines and chemokines. Figure 3A showed that both A549 and SPC-α-1 CM concentration stimulated histamine which is released from A549 and SPC-α-1CM, respectively. The MCs was treated with A549 and SPC-α-1 CM to validate whether NSCLC CM could enhance transcriptional levels. Figure 3B showed that the protein levels of IL-6, TNF-α, and CXCL8/IL-8 were significantly up-regulated in A549 and SPC-α-1 CM for 24 h.

4 MC CM induces EMT and invasion ability of NSCLC cells

We could obtain the HMC-1 CM which were activated by A549 CM or SPC-α-1 CM. Figure 4A showed that both MC CM and transforming growth factor beta (TGF-β) was a positive reference [18], and they induced significantly different morphology in A549 and SPC-α-1 cell line, which is EMT. Furthermore, we examined the protein level of EMT transcription factors Zeb-1, epitheliom marker E-cadherin, and interstitial marker Vimentin in NSCLC cells treated with MC CM, which were collected at different time points (3, 12, and 24 h). These results showed that such treatment induced EMT in each analyzed NSCLC cell line (Figure 4B). The result showed that MC CM enhanced the A549 and SPC-α-1 migration (Figure 4C), which was a typical EMT. These characteristics indicated that MC CM might release some soluble factors to trigger EMT and migration.

Figure 2: Recruitment of MCs by NSCLC cells: a role of CCL5. (A) HMC-1 was incubated on the top chamber in a transwell system with fibronectin and CM from the NSCLC cell lines A549, SPC-α-1 in the lower chambers, human bronchial epithelial cells(HBECs) CM was used as a negative reference. Migrated cells were fixed and stained with crystal violet. (B) CCL-5 expression in human NSCLC cell lines was assessed by ELISA. The A549, SPC-α-1 cell lines released high expressions of CCL-5 compared to the normal HBECs, all of the experiments are in triplicate determinations (Means ± S.D.). (C) Migration of MCs in response to A549 CM was performed with or without anti-CCL-5 blocking antibodies. The anti-CCL-5 reverse the role of NSCLC cells induce mast cell migration. Average results of three independent assays. (**P<0.01 and ***P<0.001)
Figure 3: NSCLC cells induce mast cell activation. (A) The release of histamine of MCs was assessed by ELISA. A549 and SPC-α-1 CM stimulated histamine release of MCs compared to the HBECs CM. The expression level values were conducted in triplicate, and the average value of the means ± S.D. (B) ELISA assay was utilized to examine the protein levels of soluble factors and chemokines of HMC-1 cells compared with NSCLC cell CM. HBECs CM was considered as a negative control. The expression level values were conducted in triplicate, and the data represent the means ± S.D. (**P<0.01 and ***P<0.001)

Figure 4: MC CM induces EMT and invasion ability of NSCLC cells. (A) A549 and SPC-α-1 cells were incubated with no serum for 12 h and treated with MC CM or serum-deprived (NT) medium for 24 h, TGF-β as a positive control. MC CM or TGF-β treated cells showed a fibroblast-like morphology, it was the phenotype of EMT. (B) The NSCLC were cultured in serum-free medium for 12 h and treated with MC CM or left untreated (NT) for the marked times. Immuno-blots assay was analyzed to assess the production of EMT transcription factors and EMT markers. β-actin was used as a control. (C) Transwell assays of the indicated cells in NSCLC CM or MC CM validated that MC CM induce tumor migration. Each experiment was measured in triplicate for the average of values. (NT: not treated; **P<0.01)
5 IL-8 is the main MC-derived soluble factor inducing EMT and migration in NSCLC cells

We showed increased protein level of IL-6, TNF-α, and IL-8 in tumor-educated MCs. In addition, we suggested that IL-6, IL-8, and TNF-α had the ability to induce EMT transcription factor ZEB1 as well as epithelium marker E-cadherin and interstitial marker Vimentin expression in A549 and SPC-α-1 cells (Figure 5A). Inhibiting IL-8, but no change of IL-6 or TNF-α from MC CM, significantly prevented cell migration of NSCLC, and the migration ability was recovered by IL-8 addition (Figure 5B). These data suggested that IL-8 was the key mediators for MC CM-mediated EMT in NSCLC. Accordingly, we found that NSCLC cell lines were significantly increased levels of IL-8 receptors, CXCR1 and CXCR2 (Data not shown). These data demonstrated that tumor-educated MCs released IL-8, subsequently induced CXCR1 and CXCR2 expression, eventually elevated tumor EMT and migration in NSCLC.

6 Molecular mechanisms involved in IL-8-induced EMT and invasion in NSCLC cells

Then we investigated which signaling pathway was involved in IL-8 and MC CM-induced EMT and migration. It is well known that overexpression of Wnt/β-catenin is correlated with worse NSCLC prognosis [19]. In our previous study, we have proved that miR-33b restrains the Wnt/β-catenin signaling activation in lung adenocarcinoma cells and then inhibits EMT, migration and growth of tumor cells. Knockdown of β-catenin in NSCLC cells inhibits the tumor and migration [14]. We found that IL-8 induced the activation of β-catenin in SPC-α-1 using the MC CM culture with A549 cell lines (Figure 6A-B). Knockdown of β-catenin significantly inhibited IL-8-induced EMT by assessing ZEB1, E-cadherin, Vimentin mRNA expression (Figure 6C). Furthermore, the results showed that β-catenin-siRNA inhibit tumor migration (Figure 6 D). The same data were validated in SPC-α-1 (Data not shown). Our results indicated that IL-8 activated EMT and migration through Wnt/β-catenin pathway in NSCLC cells.

7 Xenografts of human NSCLC cells can recruit circulating mast cells

To confirm whether HMC-1 could be recruited into tumor region in vivo, we injected A549 cell (1 × 10^7) subcutaneously nude mice. When the tumors was measured approximately 40 mm^3, and 5 × 10^6 HMC-1 cells were intravenously injected into mice tail. To further validate the role of role of CCL5 in the recruitment of MCs in NSCLC in vivo, the CCL5-siRNA were synthesized by Shanghai...
GenePhama Co., Ltd. (Shanghai, China) and transfected to A549 cell. The results showed only injection of HMC-1 cells were recruitment to the tumor, but not in non-injected controls. However, the down-regulation of CCL5 in A549 cell, the role of HMC-1 cells recruitment to the tumor was inhibited (Figure 7B). Scarcely any MCs were existed at the 1 d after injection (only 5-7 in the whole lung tissue), but their number were significantly enhanced at 7d post injection (Figure 7A).

Figure 6: Molecular mechanisms responsible for IL-8-induced EMT and invasion in NSCLC cell. (A) The indicated NSCLC cultured in serum-free medium for 12 h, stimulated with MC CM or IL-8 (50 ng/ml) or un-treated (NT). Signaling pathway excitation was assessed with β-catenin. Anti-GAPDH antibodies were applied as a contrast. (B) qRT-PCR was used to test the β-catenin mRNA level. The results showed that IL-8 induced the activation of β-catenin , especially combined with MC CM. (C) The A549 cell was starved for 12 hours and treated with MC CM or combined with IL-8, or transferred with β-catenin-siRNA to assess ZEB1, E-cadherin and vimentin mRNA expression. Transferred with β-catenin-siRNA group significantly inhibited IL-8 induced ZEB1, E-cadherin and vimentin mRNA expression. (D) Transwell assay also showed β-catenin-siRNA efficiently reduced A549 cell migration. **P<0.05 compared with untreated (NT) cells; §P<0.05 compared with IL-8-treated cells.

Figure 7: Xenografts of human NSCLC cells can recruit circulating mast cells. (A) 5 × 10^6 HMC-1 cells were intravenously injected into nude mice tail bearing A549 xenografts. The mice were sacrificed at different time points after injection. The tryptase was calculated in the whole tumor sections. The average of tryptase cells was obtained by evaluating at least three times. (B) Immunofluorescence analysis of A549 + HMC-1 and CCL5-siRNA- A549 + HMC-1 xenografts at 7d indicates much more HMC-1 in tumor sections. A549 xenografts were absolutely negative for tryptase. (***P<0.01)
8 Mast cells enhance the xenograft growth and EMT of human NSCLC cells in vivo

To further clarify the underlying mechanism, we injected $1 \times 10^7$ A549 cells, $1 \times 10^6$ HMC-1 cells or mixture of both cells (A549 and HMC-1) into the BALB/c nude mice. As shown in Figure 8A, when A549 cells were co-injected with HMC-1 cells, tumor volume was obviously higher than those of A549 cells injection alone ($P < 0.001$). Immunohistochemistry assay showed that the expressions of ZEB1, β-catenin and vimentin were increased, whereas E-cadherin levels were down-regulated after 21 d injection in cells mixture xenografts, which was consistent with the data in vitro (Figure 8B). The qRT-PCR data was uniform with western blot result (Figure 8C and D). Taken together the results showed that MC induced tumor growth by promoting EMT of NSCLC cells.

Discussion

MCs are infiltrated in a variety of tumors which they regulate antitumorigenic or protumorigenic role [8,20-21]. Chronic inflammatory reactions predispose to mediate cancer progress by either inhibiting or promoting tumor EMT and metastasis [3]. This response involves chemokines CCL5, and CCL5 is also identified in human NSCLC samples, which mediates TGF-β expression, where it correlates with lung adenocarcinoma invasion [22]. RUNX3 is the up-stream receptor of CCL5, and decreasing the RUNX3 expression can improve cancer-associated bone destruction in NSCLC [16]. Interestingly, CCL5 induces human MC migration by activating CCR1 and CCR4, which are the MC receptors located in the surface of human umbilical cord blood derived MC or human lung tissue derived MC [17,22]. We discovered that the density of MC is much higher in human NSCLC tissue than in normal lung tissue. This phenomenon may be explained by the following reasons: once MC recruits to the tumor tissue can increase proliferation of resident mast cells and NSCLC can induce MC migration to the tumor micro-environment. According to chemoattraction assays, we show that NSCLC may play a potential role for MCs chemoattractant. This effect needs CCL5 which is derived from NSCLC cell, and it is restrained by the anti-CCL5 antibody. Interestingly, HMC-1 cells are recruited to NSCLC cell xenografts after injection into the tail vein of nude mice. When mixed NSCLC cells and HMC-1 cells were subcutaneously transplanted, and it can promote tumor growth. This result proves that NSCLC cells provide MCs with a suitable condition that eventually improves their survival and cell growth.

Figure 8: MCs strengthen the xenograft growth and EMT of human NSCLC cells in vivo. (A-B) Xenograft growth of A549 in the presence or absence of MC line (HMC-1) was checked by calculating tumor size every three days (n=6 per group). HMC-1 alone could not produce tumors. However, the combined HMC-1 and A549 cell caused an obvious enhancement in tumor volume. (C-D) Expressions of ZEB1, Vimentin, E-cadherin, β-catenin mRNA and protein were performed in tumor xenografts by western blot and qRT-PCR. All data are indicated as mean ± SD in triplicate in each experiments (*P<0.05, **P<0.01 and ***P<0.001).
Figure 9: MC-dependent IL-8-Wnt/β-Catenin pathway that sustains EMT and migration of NSCLC cells.

We also show that NSCLC cells CM induces MC activation by secreting a variety of cytokines and chemoattractants such as IL-6, TNF-α, GM-CSF, CXCL8/IL-8, and CXCL1/IP10, which can aggravate the malignant phenotype of cancer cells [12]. In the present research, MC-derived soluble factors mediate NSCLC cell EMT and migration. Moreover, we stimulate MCs with NSCLC cell-derived CM and find some cytokines significantly upregulated compared with vehicle group including IL-6, IL-8, and TNF-α, which is consistent with the expression in NSCLC cells for inducing EMT and migration. Interestingly, we also discover that IL-8 is needed for modulating MC CM migration in A549 cells by immune depletion experiments. Consistently, CXCR1 and CXCR2 are expressed in NSCLC cells. There are many explanations, and we think different inflammatory factors or other stress-related cytokines result in IL-8 activation from MCs in a cancer microenvironment [19, 23]. In the present study, we suggest that IL-8 serves as the main MC-derived cytokine inducing EMT and migration in NSCLC cells.

Furthermore, we explore the underlying mechanism that IL-8 induces NSCLC migration and EMT. IL-8 not only involves in the innate and adaptive immunity in mammals, but also is associated with a variety of activation in many cancers. Specifically, IL-8 is involved in many kinds of tumor growth due to its ability to trigger cell invasion, migration and angiogenesis [24-26]. IL-8 also has been proved for involving in tumor EMT [27]. Here, we suggest that IL-8 is increased in plasma of NSCLC patients compared to the normal control especially with worse prognosis [28-29]. IL-8, as the up-stream of Wnt/β-Catenin, can induce the activation of Wnt in tumor and reduce the phosphorylation of β-Catenin degradation to induce tumor EMT and migration [19]. It is reported that IL-32 secreted by gastric cancer cells can induce the downstream chemokines IL-8 expression to promote tumor metastasis by modulating the Wnt/β-Catenin signaling pathway [30]. IL-8 can also play the role of promoting tumor EMT and metastasis by targeting Wnt/β-Catenin pathway in ovarian cancer cells [31]. In our study, knockdown of β-Catenin impedes EMT transcription factors ZEB1 accumulation and migration of NSCLC cells. Our data demonstrate that MCs improve IL-8-Wnt/β-Catenin signaling pathway that induces EMT and migration in NSCLC cells. Consistent with these results, β-Catenin induced NSCLC proliferation, EMT and invasion in NSCLC which validate our data [14,32-33]. Although the NSCLC cells exhibit diverse phenotypes of mast cell density, there is still no significant relationships with estimated clinical outcome. Moreover, in NSCLC samples, we also obtain that MC density is positive correlation with the prognosis. High density of MC in NSCLC is worse overall survival (OS). In fact, NSCLC prognosis is usually complicated, most of patients are cured upon surgery and chemotherapy. In future, the
immunotherapy, MC inhibitor chromoglycate (Cromolyn) maybe serves as a novel target to impede migration of NSCLC.

MCs are a main source of IL-8 in NSCLC, as described in the present research. However, we still cannot eliminate other kinds of cell types which play a vital role to construct the tumor microenvironment. It may stand for that there is an alternative source of IL-8 instead of NSCLC. And this research is needed for further investigation. Original data suggest that among all kinds of immune cells which can infiltrate NSCLC, macrophages produces high expressions of IL-8 production. There is a report indicates that tumor-associated macrophages (TAMs) induce high level of IL-8 in NSCLC, and IL-8 in turn promotes NSCLC angiogenesis and the survival of patients [34]. Moreover, TAMs are also rich in human NSCLC, where their density is associated with cancer metastasis [35]. It means that different immune cells can induce NSCLC growth. In our preliminary data indicate that TAMs can produce high level of IL-8 in NSCLC. It is imperative for us to further investigation.

Taken together, our data identify NSCLC release CCL5, which receptor located at the MCs surface, combined its receptor and activated MCs secret IL-8. MC-dependent IL-8-Wnt/β-Catenin pathway that induces EMT and migration of NSCLC cells (Figure 9). The obstruction of this circuit can be used for the precise therapy of advanced NSCLC. However, our study also came up with several questions. First and foremost, are MCs an absolute demand for NSCLC formation? Second, the underlying mechanism of NSCLC releases CCL5 to recruit mast cell to tumor micro-environment is still unknown. We are going to perform experiments of impeding MC development in animal models or cells to further solve this issue both in vivo and in vitro in future.

Abbreviations

MCs: Mast cells; NSCLC: Non-small cell lung cancer; EMT: Epithelial-to-mesenchymal transition; HMC-1: Human mast cell-1; CCL5: C-C motif chemokine ligand 5; CM: Conditioned medium; TGF-β: Transforming growth factor beta; TAMs: Tumor-associated macrophages.

Acknowledgements

Ethics approval and consent to participate

This study was submitted to and approved by Animal Experimental Ethical Inspection of the Animal Center of Hunan Cancer Hospital. All protocols were approved by the institutional review board for animal experiments of Hunan Provincial People’s Hospital.

Funding

This work was supported in part by the National Youth Science Foundation of China (No.81802278 to Q.J.J.) and National Youth Science Foundation of China (No.81802814 to H.J.F.).

Authors’ contributions

J.J.Q. and T.L.C. performed experiment. J.J.Q., J.F.H., X.B.L., Z.Y.S. and L.L. provide of study material, collection of data, data analysis and interpretation, manuscript writing; W.Y.W., K.Y.L, and N.Y. conception and design, manuscript writing, final approval of manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

[1] Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.
[2] Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94
[3] Quasi DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437
[4] Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell.2012;21(3):309-322.
[5] Palucks AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016;164(6):1233-47.
[6] Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008; 9: 1215–1223
[7] Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999; 13: 1382-1397.
[8] Vacciano C, Liotti F, Previte N, Cali G, Franco R, Collina F, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015;34(40):5175-86.
[9] Nowak EC, de Vries VC, Wasiak A, Ahoren C, Bennett KA, Le Mercier I et al. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med. 2012; 209: 2127-2135.
[10] Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005;23(35):8959-67.
[11] Hu G, Wang S, Cheng P. Tumor-infiltrating tryptase+ mast cell predict unfavorable clinical outcome in solid tumors. Int J Cancer. 2018;144(2):813-821.
[12] Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Previte N. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203-15.
[13] Romagnani P, de Paulis A, Beltrame C et al. Tryptase-chymase double-positive human mast cells express the eosin receptor CCRC and are attracted by CCR3-binding chemokines. Am J Pathol. 1999. 155:1195-204.
[14] Qu J, Li M, An J, Zhao B, Zhong W, Gu Q, Cao L, Yang H, Hu C. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling. Int J Oncol. 2015; 47(6):2141-52.
[15] Qu J, Do DC, Zhou Y, Luczak E, Mitzner W, Anderson ME, Gao P. Oxidized CaMKII promotes asthma through the activation of mast cells. JCI Insight. 2017;2(1): e90139.
[16] Kim HH, Park J, Lee SK, Kim KR, Park KK, Chung WY. Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer. J Pathol. 2015;237(4):520-31.
[17] Bradding P, Arthur G. Mast cells in asthma--state of the art. Clin Exp Allergy. 2010;40(2):194-263.
[18] Cheng T, Hu C, Yang H, Cao L, An J. Transforming growth factor-β-induced miR-143 expression in regulation of non-small cell lung cancer cell viability and invasion capacity in vitro and in vivo. Int J Oncol. 2014;45(5):1977-88.
[19] Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735-41.
[20] Attarba S, Roy A, Westerkam B, Tchougouyouva E3. Mast cells modulate proliferation, migration and stemness of glioma cells through...
down-regulation of GSK3β expression and inhibition of STAT3 activation. Cell Signal. 2017;37:81-92.

[21] Marichal T, Tsai M, Call S J. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunology Research; 2013;1(5):269-79.

[22] Bergot AS, Ford N, Leggatt GR, Wells JW, Frazer IH. HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5-mediated recruitment of mast cells. PLoS Pathog. 2014;10(10):e1004466.

[23] Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002; 72: 847-855.

[24] Campbell LM, Maxwell PJ, Waugh DJ. Rationale and means to target pro-inflammatory interleukin-8 (CCL8) signaling in cancer. Pharmaceuticals. 2013; 6: 929-959.

[25] Lesage J, Saurez-Carmona M, Neyrinck-Leglandier D, Grelet S, Blacher S, Hunziker W, Birembaut P, Noel A, Nawrocki-Raby B, Gilles C, Polette M. Zonula occludens-1/NF-κB/CXCL8: a new regulatory axis for tumor angiogenesis. FASEB J. 2017;31(4):1678-1688.

[26] Uzunoglu FG, Yavari N, Bohn BA, Nentwich MF, Reeth M, Pantel K, Perez D, Tsui TY, Bockhorn M, Mann O, Izbicki JR, Wikman H, Vashist YK. C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC. Lung Cancer. 2013;81(1):123-9.

[27] Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012; 8: 713-722.

[28] Barrera L, Montes-Servín E, Barrera A, Ramírez-Tirado LA, Salinas-Parrera F, Bañales-Méndez JL. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 2015;26(2):428-3.

[29] Samnamed MF, Perez-Gracia JL, Salascher KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;26(8):1988-1995.

[30] Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 2014;20(9):2276-88.

[31] Yang CT, Li JM, Li LF, Ko YS, Chen JT. Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through β-catenin signaling pathway. Cell Death Dis. 2018;9(4):425.

[32] Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9(2):729-37.

[33] Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2005;23(5):953-64.